In an ever-evolving healthcare landscape, continuous collaboration is key to driving meaningful advancements. The ongoing partnership with Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ) exemplifies this approach, as we leverage the power of AI to revolutionize oncology research and development. Below, we delve into how this partnership is transforming research into viable medical solutions, particularly in the field of AI-driven cancer diagnostics, and the innovative steps we are taking to bridge the gap between academic research and pharmaceutical application.

Our Mission: Innovating Together for a Healthier Future

The primary objective of this partnership is to leverage AI-based research to develop medical products, specifically Software as a Medical Device (SaMD), to support researchers in transforming their ideas into viable medical solutions by supporting them with technical and regulatory expertise (ISO13485).

The partnership aims to bridge the gap between research and pharmaceutical companies by utilizing PAICON’s Platform and Project services particularly to accelerate AI-based innovation in oncology and turn project-based research collaborations into long-term partnerships and strategic alliances.

Focus Areas: Pioneering AI-Driven Oncology Solutions

At the heart of this partnership is a commitment to bridging the gap between academic research and the pharmaceutical industry. Together, we focus on developing Software as a Medical Device (SaMD) solutions, with a particular emphasis on oncology. Within this framework, PAICON together with UKHD is dedicated to advancing the distinction between microsatellite stable and microsatellite instable tumors using machine learning based on annotated histology slides. This innovative approach will enhance decision-making for pathologists, ultimately reducing time-to-therapy for patients and improving their chances of successful outcomes.

Our long-term goal is to certify this algorithm as a SaMD in collaboration with pharmaceutical partners. To achieve this, PAICON is leveraging its Data Hub to access diverse datasets, providing AI expertise, and leading the development of algorithms and prototypes on the PAICON platform, all within the framework of ISO13485 standards.

Integration of PAICON Services with UKHD and DKFZ

PAICON’s Data Lake and Data Exchange Service will play a central role in ensuring that all relevant data is easily accessible and shareable among partners, fostering collaboration and innovation. The PAICON platform will be utilized to streamline AI model training, enabling researchers and developers to efficiently build and refine AI-based medical products that can be translated into clinical practice.

Additionally, PAICON’s technical expertise will serve as a bridge across all collaborative activities, ensuring that the data infrastructure and AI technologies are seamlessly integrated into research and product development workflows. This expertise will support the entire lifecycle of AI-driven innovations, from data management to model deployment in clinical settings.

Key Outcomes: Advancing Cancer Care Through AI

This partnership aims to deliver AI-driven SaMDs that will enhance the ability to diagnose, treat, and manage cancer more effectively. By establishing a robust framework for data sharing and AI model development, we are setting the stage for future research and product development.

The ultimate goal is to create a streamlined pipeline that transitions research innovations into market-ready medical products, leveraging PAICON’s technology and services to bring these innovations to life.

A Message to the Public: A New Era in Cancer Research

The partnership between PAICON, UKHD, and DKFZ represents a significant advancement in integrating AI with medical research, particularly in the fight against cancer. By leveraging PAICON’s Data Lake, data exchange service, and AI-model training platform, this partnership is set to accelerate the development of innovative medical technologies that can improve patient outcomes.

Our partnership with UKHD and DKFZ not only enhances the ability to bring cutting-edge research to life but also strengthens the bridge between academic research and pharmaceutical applications. Together, we are ensuring that new discoveries are quickly and effectively translated into medical solutions that can make a real difference in patients’ lives.

Explore Data Collaboration Opportunities with PAICON

As we continue to bridge the gap between research and industry, PAICON invites you to explore collaborative opportunities that can drive innovation in healthcare. Whether you’re a pharmaceutical company seeking specialized data for AI model development or a healthcare provider looking to partner on cutting-edge solutions, PAICON offers tailored data acquisition and comprehensive support to meet your needs.

Ready to make an impact? Contact us today at info@paicon.com and join our network of collaborators!